SPRY2

Across TCGA pan-cancer cohorts, SPRY2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPRY2 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SPRY2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SPRY2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where SPRY2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	1.000	0.549	.038	6	view →
LUAD	OS	Quartile	All	0.501	1.000	.037	6	view →
PDAC	DFS	Median	All	0.440	0.984	.024	3	view →
LSCC	DFS	Quartile	III,IV	1.000	0.529	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPRY2–HNSC (DFS)

Open the HNSC breakdown →